We have to take a hit in the short term but in the long term, it will be good for us, says Dabur India Chairman.

Leading personal care companies Godrej Consumer Products Ltd, Marico, Emami, Dabur and HUL have been tapped as the founding family behind S...

J&J's talc came under controversy once again in India when Indian drug regulators ordered the testing of the talc to check if it contained ...

This is Manjushree Technopack’s first acquisition and will pit it directly against multinational packaging company Tetrapak.

Dabur said the products on which US FDA has issued import alerts were unauthorised exports by an independent exporter and the company has t...

Alembic Pharmaceuticals, the newly-listed subsidiary of the 104-year Vadodara-headquartered group, will invest Rs 100 crore in a drugs faci...

Reckitt Benckiser would absorb top 10 executives of Paras Pharmaceuticals and retain 200 people working at its Baddi plant in an in-princip...

FMCG firm Emami is expecting a 15-20 per cent growth in its Chyawanprash segment even as its plans to consolidate all its brands under the ...

German drug co recalled two batches of cancer drug made by its Indian arm on cross-contamination.

Private equity firms Actis and Sequoia that together hold 70% stake are looking to sell their holding at an estimated price of $700 mn.

FMCG major Dabur on Tuesday said it has tied up with a Belgium firm for technical collaboration to reduce carbon emissions in its plants an...

Dabur India on Friday announced the acquisition of 72.15% of women’s skin-care company Fem Care Pharma (FCPL) for Rs 203.7 crore in an all-...

Fresenius Kabi, which acquired the Burmans’ pharma business early this year, will invest around 30 euros million in the active pharmaceutic...

Fresenius Kabi, which acquired Dabur Pharma, is looking to expand the latter's oncology business globally with plans of investing up to 30 ...

German co Fresenius Kabi acquired the stake in Dabur Pharma for around Rs 872 cr. With this, the Burman family exits pharmaceutical biz. Go...

Stepping up its overseas expansion, Dabur Pharma has made a foray into the anti-cancer drug market in Pakistan and Turkmenistan.

Spurred by better product mix and controlled expenses in manufacturing, Dabur Pharma's net profit in the fourth quarter ended March 31 grew...